AALL1732: the high-risk study
Updated September 2026. Citations at bottom of page.
AALL1732 · NCT03959085
Also known as: 1732, COG AALL1732
This page is a placeholder. I have not started the real write-up of AALL1732 yet. If your kid has high-risk B-ALL, the roadmap may say “1732”: it is the Children's Oncology Group study asking whether adding inotuzumab ozogamicin to the usual chemotherapy keeps more kids in remission.
Placeholder: not started yet
I have not written this page yet. I wrote AALL1731 first because that is the study my kid is on, and I plan to build this one the same way: the pathways, the numbers, and what the study can and cannot say about one child. Until then, the few paragraphs below are only a placeholder so the page is not empty, and your kid's roadmap is the document to trust.
The short version
AALL1732 is a Children’s Oncology Group phase 3 study for kids and young adults newly diagnosed with high-risk B-ALL (and some related diagnoses, B-lymphoblastic lymphoma and mixed phenotype acute leukemia). The question it asks is whether adding inotuzumab ozogamicin, an antibody that carries a toxin into leukemia cells, to the usual post-induction chemotherapy keeps more kids in remission than the chemotherapy alone. Kids are split by chance between the two arms after induction.
If your kid’s roadmap says 1732, the drugs, phases and timing on that roadmap are the ones that count. This page is background, not a substitute.
What I have and have not checked yet
- I have read the registry entry and the PDQ summary. I have not yet gone through the conference abstracts and papers the way I did for 1731.
- The study was still enrolling the last time I checked. Results for the main question are not published yet, so there are no odds to show. When there are, they will go here with the population and follow-up stated.
- The inotuzumab page under How the drugs work explains what the drug does inside the body.
What it can’t tell you about your kid
A study describes a group. Your kid’s response, side effects and timing are their own. Where this page and the roadmap your team gave you differ, the roadmap is the one written for your kid.